Pluri (PLUR) Competitors $5.56 +0.06 (+1.00%) Closing price 03:59 PM EasternExtended Trading$5.63 +0.06 (+1.17%) As of 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLUR vs. ACRS, NVCT, NLTX, MOLN, TIL, BIOA, CGEN, ALEC, GALT, and ACOGShould you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Aclaris Therapeutics (ACRS), Nuvectis Pharma (NVCT), Neoleukin Therapeutics (NLTX), Molecular Partners (MOLN), Instil Bio (TIL), BioAge Labs (BIOA), Compugen (CGEN), Alector (ALEC), Galectin Therapeutics (GALT), and Alpha Cognition (ACOG). These companies are all part of the "pharmaceutical products" industry. Pluri vs. Its Competitors Aclaris Therapeutics Nuvectis Pharma Neoleukin Therapeutics Molecular Partners Instil Bio BioAge Labs Compugen Alector Galectin Therapeutics Alpha Cognition Pluri (NASDAQ:PLUR) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation. Do analysts prefer PLUR or ACRS? Pluri presently has a consensus price target of $12.00, indicating a potential upside of 115.63%. Aclaris Therapeutics has a consensus price target of $8.71, indicating a potential upside of 449.80%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aclaris Therapeutics is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Is PLUR or ACRS more profitable? Aclaris Therapeutics has a net margin of -732.42% compared to Pluri's net margin of -2,563.29%. Aclaris Therapeutics' return on equity of -30.73% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Pluri-2,563.29% -4,191.91% -85.40% Aclaris Therapeutics -732.42%-30.73%-22.74% Which has more risk & volatility, PLUR or ACRS? Pluri has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Do insiders and institutionals hold more shares of PLUR or ACRS? 16.6% of Pluri shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 25.9% of Pluri shares are owned by insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger earnings & valuation, PLUR or ACRS? Pluri has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPluri$330K132.04-$20.89M-$5.53-1.01Aclaris Therapeutics$18.72M9.17-$132.07M-$1.39-1.14 Does the media favor PLUR or ACRS? In the previous week, Aclaris Therapeutics had 2 more articles in the media than Pluri. MarketBeat recorded 4 mentions for Aclaris Therapeutics and 2 mentions for Pluri. Aclaris Therapeutics' average media sentiment score of 0.77 beat Pluri's score of 0.64 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pluri 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAclaris Therapeutics beats Pluri on 12 of the 17 factors compared between the two stocks. Get Pluri News Delivered to You Automatically Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLUR vs. The Competition Export to ExcelMetricPluriMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.57M$2.96B$5.57B$9.02BDividend YieldN/A2.44%5.25%4.03%P/E Ratio-1.0121.1627.2120.15Price / Sales132.04260.59416.26185.35Price / CashN/A41.8337.0657.97Price / Book5.577.768.085.60Net Income-$20.89M-$54.96M$3.16B$248.50M7 Day Performance-3.22%5.99%3.74%5.11%1 Month Performance13.46%4.41%3.88%7.58%1 Year Performance1.00%6.36%34.26%21.53% Pluri Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLURPluri3.5132 of 5 stars$5.57+1.0%$12.00+115.6%-5.0%$43.57M$330K-1.01150News CoverageACRSAclaris Therapeutics2.7988 of 5 stars$1.42-3.4%$9.71+584.1%+22.2%$159.17M$18.72M-1.02100Analyst ForecastGap UpNVCTNuvectis Pharma3.2832 of 5 stars$7.47-1.1%$17.00+127.6%+28.7%$157.75MN/A-6.618Positive NewsNLTXNeoleukin TherapeuticsN/A$16.16-2.5%N/A-44.9%$151.87MN/A-5.2090High Trading VolumeMOLNMolecular Partners2.8146 of 5 stars$3.79+0.8%$12.00+216.6%-44.3%$151.81M$5.65M-1.97180TILInstil Bio3.1516 of 5 stars$20.83-9.3%$119.00+471.3%+152.5%$150.66MN/A-1.74410BIOABioAge LabsN/A$4.13-1.7%N/AN/A$150.57MN/A0.00N/ANews CoverageCGENCompugen1.4067 of 5 stars$1.78+7.2%$4.00+124.7%-5.1%$148.13M$27.86M-11.1370Positive NewsALECAlector4.0712 of 5 stars$1.40-5.4%$4.00+185.7%-65.4%$147.99M$100.56M-1.11270News CoverageGALTGalectin Therapeutics1.1149 of 5 stars$2.11-9.4%$6.00+184.4%-5.1%$147.47MN/A-2.939News CoverageGap UpACOGAlpha Cognition1.5021 of 5 stars$9.33+2.5%$20.00+114.4%N/A$145.86MN/A-7.77N/A Related Companies and Tools Related Companies Aclaris Therapeutics Competitors Nuvectis Pharma Competitors Neoleukin Therapeutics Competitors Molecular Partners Competitors Instil Bio Competitors BioAge Labs Competitors Compugen Competitors Alector Competitors Galectin Therapeutics Competitors Alpha Cognition Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLUR) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
